Steward Partners Investment Advisory LLC Increases Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Steward Partners Investment Advisory LLC increased its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report) by 0.7% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 16,702 shares of the medical equipment provider’s stock after purchasing an additional 121 shares during the period. Steward Partners Investment Advisory LLC’s holdings in Zimmer Biomet were worth $2,033,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ZBH. Quantbot Technologies LP purchased a new position in shares of Zimmer Biomet in the 3rd quarter worth $1,730,000. Avantax Advisory Services Inc. grew its position in Zimmer Biomet by 10.1% during the third quarter. Avantax Advisory Services Inc. now owns 3,940 shares of the medical equipment provider’s stock valued at $442,000 after buying an additional 363 shares during the period. Western Wealth Management LLC purchased a new stake in Zimmer Biomet during the third quarter valued at approximately $481,000. Amalgamated Bank raised its position in Zimmer Biomet by 3.0% in the third quarter. Amalgamated Bank now owns 56,166 shares of the medical equipment provider’s stock worth $6,303,000 after acquiring an additional 1,631 shares during the period. Finally, Greatmark Investment Partners Inc. boosted its stake in shares of Zimmer Biomet by 2.7% during the 3rd quarter. Greatmark Investment Partners Inc. now owns 13,810 shares of the medical equipment provider’s stock worth $1,550,000 after acquiring an additional 365 shares during the last quarter. Institutional investors own 88.89% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on ZBH. StockNews.com cut Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a research report on Monday, February 19th. Barclays cut their price target on Zimmer Biomet from $130.00 to $125.00 and set an “underweight” rating for the company in a research note on Friday. Royal Bank of Canada restated an “outperform” rating and issued a $140.00 price objective on shares of Zimmer Biomet in a research report on Friday, February 9th. TheStreet upgraded Zimmer Biomet from a “c” rating to a “b-” rating in a research report on Thursday, February 8th. Finally, Evercore ISI upped their price target on Zimmer Biomet from $125.00 to $130.00 and gave the stock an “in-line” rating in a research note on Thursday, April 4th. One analyst has rated the stock with a sell rating, nine have given a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, Zimmer Biomet currently has an average rating of “Hold” and a consensus target price of $133.75.

Get Our Latest Stock Report on ZBH

Zimmer Biomet Stock Up 0.6 %

Shares of NYSE:ZBH opened at $115.15 on Friday. The company has a 50-day moving average price of $122.33 and a 200 day moving average price of $121.96. The company has a current ratio of 1.66, a quick ratio of 0.80 and a debt-to-equity ratio of 0.38. Zimmer Biomet Holdings, Inc. has a 12 month low of $102.00 and a 12 month high of $147.50. The company has a market cap of $23.69 billion, a price-to-earnings ratio of 24.92, a PEG ratio of 2.08 and a beta of 1.03.

Zimmer Biomet (NYSE:ZBHGet Free Report) last announced its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 EPS for the quarter, topping analysts’ consensus estimates of $1.87 by $0.07. Zimmer Biomet had a return on equity of 12.70% and a net margin of 12.93%. The firm had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. During the same quarter in the previous year, the business earned $1.89 EPS. The company’s quarterly revenue was up 3.2% on a year-over-year basis. As a group, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.1 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Stockholders of record on Wednesday, June 26th will be issued a $0.24 dividend. The ex-dividend date is Wednesday, June 26th. This represents a $0.96 annualized dividend and a dividend yield of 0.83%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 20.78%.

Zimmer Biomet Company Profile

(Free Report)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

See Also

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBHFree Report).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.